Highlights of This Issue 6367

SPECIAL FEATURES

CCR Translations

6369 Therapeutic Oligonucleotides: The Road Not Taken
Cy A. Stein and Sanjay Goel
See commentary p. 6582

Molecular Pathways

6373 The Role of Erythropoietin and Erythropoiesis-Stimulating Agents in Tumor Progression
Benjamin D. Hedley, Alison L. Allan, and Anargyros Xenocostas

6381 TLX1-Induced T-cell Acute Lymphoblastic Leukemia
Kim De Keersmaecker and Adolfo A. Ferrando

CCR Focus

6388 Antibody Conjugates: The Future Is Now
Susan E. Bates

6389 Antibody Conjugate Therapeutics: Challenges and Potential
Beverly A. Teicher and Ravi V.J. Chari

6398 Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox
Robert J. Kreitman and Ira Pastan

6406 Antibody-Radiouclide Conjugates for Cancer Therapy: Historical Considerations and New Trends
Martina Steiner and Dario Neri

6417 Antibody-Drug Conjugates of Calicheamicin Derivative: Gentuzumab Ozogamicin and Inotuzumab Ozogamicin
Alejandro D. Ricart

6428 Brentuximab Vedotin (SGN-35)
Jessica Katz, John E. Janik, and Anas Younes

CANCER THERAPY: PRECLINICAL

6437 Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2–Positive Cancer
Patricia M. LoRusso, Denise Weiss, Ellie Guardino, Sandhya Girish, and Mark X. Sliewkowski

6448 SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies
Veronique Blanc, Anne Bousseau, Anne Caron, Chantal Carrez, Robert J. Lutz, and John M. Lambert

Review

6459 Polo-like Kinase 1 Inhibitors and Their Potential Role in Anticancer Therapy, with a Focus on NSCLC
René H. Medema, Chia-Chi Lin, and James Chih-Hsin Yang

6467 Tumor-Derived Autophagosome Vaccine: Induction of Cross-Protective Immune Responses against Short-lived Proteins through a p62-Dependent Mechanism
Christopher G. Twitty, Shawn M. Jensen, Hong-Ming Hu, and Bernard A. Fox

6482 Synergistic Action of a RAF Inhibitor and a Dual PI3K/mTOR Inhibitor in Thyroid Cancer
Ning Jin, Tianyuan Jiang, David M. Rosen, Barry D. Nelkin, and Douglas W. Ball

6490 The Novel Chemical Entity YTR107 Inhibits Recruitment of Nucleophosmin to Sites of DNA Damage, Suppressing Repair of DNA Double-Strand Breaks and Enhancing Radiosensitization
Significant Biological Role of Sp1 Transactivation in Multiple Myeloma

Dicer-Mediated Upregulation of BCRP Confers Tamoxifen Resistance in Human Breast Cancer Cells

EGRF- and VEGF(R)-Targeted Small Molecules Show Synergistic Activity in Colorectal Cancer Models Refractory to Combinations of Monoclonal Antibodies
Virginie Poindessous, Djamila Ouaret, Karima EL Ouaud, Aude Battistella, Virginie Poindessous, Djamila Ouaret, Karima EL Ouaud, Aude Battistella

Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in K-Ras Mutant Colorectal and Pancreatic Cancers
Roberta Rosa, Davide Melisi, Vincenzo Damiano, Roberto Bianco, Sonia Garofalo, Teresa Gelardi, Sudhir Agrawal, Teresa Gelardi, Sudhir Agrawal

High XRCC1 Protein Expression Is Associated with Poorer Survival in Patients with Head and Neck Squamous Cell Carcinoma
Mei-Kim Ang, Mihir B. Patel, Xiao-Ying Yin, Sneha Sundaram, Karen Fritchie, Ni Zhao, Mei-Kim Ang, Mihir B. Patel, Xiao-Ying Yin, Sneha Sundaram, Karen Fritchie, Ni Zhao

Discriminant Analysis of 18F-Fluorothymidine Kinetic Parameters to Predict Survival in Patients with Recurrent High-Grade Glioma
Mirwais Wardak, Christiaan Schippers, Magnus Dahlbom, Timothy Cloughesy, Wei Chen, Nagichettiar Satyamurthy, Johannes Czernin, Michael E. Phelps, and Sung-Cheng Huang

PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients
Tamara L. Lotan, Bora Gurel, Siobhan Sutcliffe, David Esop, Wenman Liu, Jiunfeng Xu, Jessica L. Hicks, Ben H. Park, Elizabeth Humphreys, Alan W. Partin, Misop Han, George J. Netto, William B. Isaacs, and Angelo M. De Marzo

Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin
Ahmad A. Tarhini, Paul Frankel, Kim A. Margolin, Scott Chistensen, Christopher Ruel, Janice Shipe-Spotloe, David R. Gandara, Alice Chen, and John M. Kirkwood

A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide L1Y2275796 in Patients with Advanced Cancer

Comparison of Continuous versus Categorical Tumor Measurement-Based Metrics to Predict Overall Survival in Cancer Treatment Trials
Ming-Wen An, Sumithra J. Mandrekar, Megan E. Branda, Shauna L. Hillman, Alex A. Adjei, Henry C. Pitot, Richard M. Goldberg, and Daniel J. Sargent
The work by Poindessous and colleagues shows that inhibition of EGFR- and VEGF(R)-signaling by combinations of two small molecule tyrosine kinase inhibitors (TKI), afatinib and vargatef, has synergistic activity in colorectal cancer models that are refractory to combinations of the monoclonal antibodies cetuximab and bevacizumab. Importantly, only the TKIs were able to attenuate the phosphorylation of intracellular EGFR- and VEGFR-receptors which was accompanied by the induction of apoptotic cell death as indicated by TUNEL staining (nuclear DNA in blue, apoptotic nuclei in white). This work provides a rationale for clinical trials of the afatinib and vargatef combination, even in patients with mutant KRAS. For details, see the article by Poindessous and colleagues on page 6522 of this issue.